Peg-interferon alpha induces CD56bright natural killer cell mediated reduction of HBsAg in entecavir treated chronic Hepatitis B patients

被引:0
|
作者
Shi, Aichao [1 ]
Zhang, Xiaoping [1 ]
Xiao, Fang [1 ]
Yan, Weiming [1 ]
Han, Meifang [1 ]
Chen, Tao [1 ]
Ning, Qin [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Hubei, Peoples R China
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
912
引用
收藏
页码:487A / 487A
页数:1
相关论文
共 50 条
  • [41] Effect of alpha-interferon on natural killer cell activity and lymphocyte subsets in thalassemia patients with chronic hepatitis C
    Malaponte, G
    Passero, E
    Leonardi, S
    Monte, V
    Lauria, C
    Mazzarino, C
    Sciotto, A
    Mancuso, GR
    DiGregorio, F
    Musumeci, S
    ACTA HAEMATOLOGICA, 1997, 98 (02) : 83 - 88
  • [42] Intrahepatic natural killer cell activation, but not function, is associated with HBsAg levels in patients with HBeAg-negative chronic hepatitis B
    Tjwa, Eric T. T. L.
    Zoutendijk, Roeland
    van Oord, Gertine W.
    Biesta, Paula J.
    Verheij, Joanne
    Janssen, Harry L. A.
    Woltman, Andrea M.
    Boonstra, Andre
    LIVER INTERNATIONAL, 2014, 34 (03) : 396 - 404
  • [43] Outcome of decompensated hepatitis C virus-related cirrhotic patients treated with peg-interferon alpha-2b and ribavirin. A controlled study
    Iacobellis, A.
    Siciliano, M.
    Perri, F.
    Annicchiarico, A.
    Leandro, G.
    Caruso, N.
    Accadia, L.
    Bombardieri, G.
    Andriulli, A.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S133 - S133
  • [44] The effect of interferon-free Direct-Acting Antivirals combination therapy on innate immune responses (NK cell activity and frequency of CD56dim and CD56bright NK cell subset in peripheral blood) in chronic hepatitis C patients
    Nakamura, Ikuo
    Furuichi, Yoshihiro
    Sugimoto, Katsutoshi
    HEPATOLOGY, 2017, 66 : 625A - 626A
  • [45] A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers
    d'Arondel, C
    Munteanu, M
    Moussalli, J
    Thibault, V
    Naveau, S
    Simon, A
    Messous, D
    Morra, R
    Blot, C
    Poynard, T
    JOURNAL OF VIRAL HEPATITIS, 2006, 13 (03) : 182 - 189
  • [46] Impact of liver steatosis on virological response in Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavirin (vol 21, pg 1173, 2005)
    Fabris, P
    Floreani, A
    Carlotto, A
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (11) : 1397 - 1397
  • [47] HBV RNA IN SERUM IS A PREDICTOR OF HBeAg SEROCONVERSION IN PATIENTS WITH CHRONIC HEPATITIS B RECEIVING TREATMENT WITH PEG-INTERFERON ALPHA-2a (40KD)
    van Boemmel, F.
    van Boemmel, A.
    He, H.
    Wat, C.
    Deichsel, D.
    Berg, T.
    Boehm, S.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S442 - S443
  • [48] Entecavir add-on Peg-interferon therapy plays a positive role in reversing hepatic fibrosis in treatment-naive chronic hepatitis B patients: a prospective and randomized controlled trial
    Yang, Jing-Mao
    Chen, Li-Ping
    Wang, Ya-Jie
    Lyu, Bei
    Zhao, Hong
    Shang, Zhi-Yin
    Li, Jun
    Fan, Zhen-Yu
    Wu, Sheng-Di
    Ming, Xiao
    Li, Xian
    Huang, Shao-Ping
    Cheng, Ji-Lin
    CHINESE MEDICAL JOURNAL, 2020, 133 (14) : 1639 - 1648
  • [49] Reduction of liver cell proliferation in patients with anti-HBE chronic hepatitis B treated with interferon (IFN).
    Donato, MF
    Lampertico, P
    Arosio, E
    Del Ninno, E
    Ronchi, G
    Morabito, A
    Fasani, P
    Colombo, M
    HEPATOLOGY, 1999, 30 (04) : 345A - 345A
  • [50] CONSOLIDATION THERAPY WITH ENTECAVIR CAN PREVENT POST-TREATMENT HBsAg REBOUND IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALPHA
    Brouwer, W. P.
    Sonneveld, M. J.
    Xie, Q.
    Zhang, N.
    Zeuzem, S.
    Tabak, F.
    Zhang, Q.
    Simon, K.
    Akarca, U. S.
    Streinu-Cercel, A.
    Hansen, B.
    Janssen, H. L.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S572 - S573